Table 3.
Metabolite concentrations of 130 steady state patients receiving concomitant therapy
| AZA monotherapy (n = 36) | AZA+5-ASA (n = 62) | AZA + steroids (n = 16) | Triple therapy (n = 16) | |
| Range of individual mean TGN concns | 70–591 (median 194) | 88–717 (median 227) | 118–524 (median 235) | 70–438 (median 208) |
| Range of individual mean MeMPN concns | 117–14267 (median 1567) | 30–8564 (median 993) | 228–12517 (median 1317) | 302–4850 (median 1021) |
| Dose (mg/kg) | 0.4–2.5 (median 1.8) | 0.4–2.8 (median 1.8) | 1.0–2.7 (median 2.0) | 0.6–2.6 (median 1.7) |
5-ASA, 5-aminosalicylic acid; AZA, azathioprine; MeMPN, methylmercaptopurine nucleotide; TGN, thioguanine nucleotide.
There was no significant difference in AZA dosage, TGN concentrations, or MeMPN concentrations in the four patient groups (Kruskal-Wallis, p = 0.9).
Metabolite concentrations are measured in pmol/8×108 red blood cells.